RNA m6A modification: Mapping methods, roles, and mechanisms in acute myeloid leukemia

Rong Yin; Yashu Li; Wen Tian; Fuling Zhou; Haojian Zhang

doi:10.1097/BS9.0000000000000131

RNA m⁶A modification: Mapping methods, roles, and mechanisms in acute myeloid leukemia

Blood Sci. 2022 Jul 20;4(3):116-124. doi: 10.1097/BS9.0000000000000131. eCollection 2022 Jul.

Authors

Rong Yin¹, Yashu Li², Wen Tian², Fuling Zhou¹, Haojian Zhang^{1

2}

Affiliations

¹ Department of Hematology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China.
² Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Wuhan University, Wuhan, People's Republic of China.

Abstract

N⁶-Methyladenosine (m⁶A) is the most abundant modification in eukaryotic mRNA, and plays important biological functions via regulating RNA fate determination. Recent studies have shown that m⁶A modification plays a key role in hematologic malignancies, including acute myeloid leukemia. The current growth of epitranscriptomic research mainly benefits from technological progress in detecting RNA m⁶A modification in a transcriptome-wide manner. In this review, we first briefly summarize the latest advances in RNA m⁶A biology by focusing on writers, readers, and erasers of m⁶A modification, and describe the development of high-throughput methods for RNA m⁶A mapping. We further discuss the important roles of m⁶A modifiers in acute myeloid leukemia, and highlight the identification of potential inhibitors for AML treatment by targeting of m⁶A modifiers. Overall, this review provides a comprehensive summary of RNA m⁶A biology in acute myeloid leukemia.

Keywords: Acute myeloid leukemia; Mapping; RNA m6A modification.

Copyright © 2022 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS).